Biogen Stock News

These are the stocks posting the largest moves in midday trading.

A proposal would mean that most Medicare beneficiaries won''t have access to Biogen''s Alzheimer''s disease drug Aduhelm.

Biogen plans to inundate the Centers for Medicare and Medicaid Services with public comments in response to the decision yesterday to drastically limit coverage of Aduhelm for Alzheimer''s.

Medicare seeks to only cover patients who are enrolled in clinical trials evaluating Aduhelm, a drug that costs $28,000 a year.

The stock price of Biogen Inc (NASDAQ: BIIB) fell by over 6% during intraday trading today. This is why it happened.

Futures Swing Ahead Of Today''s "Brutal" CPI Print U.S. index futures were little changed, if slightly in the green on Wednesday as investors settled into a wait-and-see mode ahead of today''s " brutal" CPI report which is expected to show the highest CPI print in nearly 40 years, a time when the fed funds rate was 11% compared to 0% now… ... and gauge the pace of Federal Reserve tightening. Consensus expects December CPI to show inflation climbing to 7.0%, a result which could see front- end fully price in a March rate hike (currently priced at 85%). Helping the overnight mood in Asia, was a moderation in China’s inflation pressures, with CPI dipping to 10.3% y/y in December, giving the central bank scope to cut interest rates to cushion the economy’s downturn just as most major nations look to tighten policy. At 730am ET, S&P futures were up 0.2% of 7.50, and Nasdaq futures rose 22 points or 0.14%, recovering toward Asia’s best levels; Dow futures were up about 0.1%. The dollar was slightly lower, extending on its recent sharp drop, while Treasury yields were steady. “All we know is that the Fed has waited too long before taking action,” said Ipek Ozkardeskaya, senior analyst at Swissquote . “If today’s inflation print is higher than expected, recent gains in equities will melt like snow in the sun,” she wrote, even though investors seemed to put aside fears that tighter policy will stifle the economic rebound and market rally after soothing words from Federal Reserve Chair Jerome Powell.

Biogen (BIIB) has extended post-market losses to trade ~9.9% lower in early trading after the U.S

Biogen (BIIB) stock declines after Medicare proposes covering FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in qualifying clinical studies.

Medicare on Tuesday said it would limit coverage of Biogen''s Aduhelm medication only to patients who are willing to enroll in qualifying clinical trials.

A proposal would mean that most Medicare beneficiaries won't have access to Biogen's Alzheimer's disease drug Aduhelm.

"Mad Money" host Jim Cramer and the 'Squawk on the Street' team weigh in on shares of Biogen and Eli Lilly after Medicare limited its coverage for antibody treatments against Alzheimer's disease.

Biogen Inc.'s BIIB, -8.99% stock sank 9.3% in premarket trading on Wednesday, the day after regulators proposed limiting access to the class of Alzheimer's disease drugs that includes the company's th

Medicare seeks to only cover patients who are enrolled in clinical trials evaluating Aduhelm, a drug that costs $28,000 a year.

Biogen Inc (NASDAQ: BIIB) is trading lower Wednesday following a U.S. Centers For Medicare listing for "Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease." Biog

In a rising market, two companies stood out on the downside.